RHYTHM BIOSCIENCES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.081 AUD | -3.57% |
|
-7.95% | -40.00% |
| 24/04 | Rhythm Biosciences Appoints CEO; Shares Down 3% | MT |
| 21/03 | Rhythm Biosciences Receives AU$2.5 Million Under Rights Issue; Shares Up 3% | MT |
| Sales 2022 | 2.43 3.71 202.54 | Sales 2023 | 3.1 4.73 258.31 | Capitalization | 90.11M 138M 7.52B |
|---|---|---|---|---|---|
| Net income 2022 | -8M -12.21M -668M | Net income 2023 | -8M -12.21M -668M | EV / Sales 2022 | 9,83,63,837 x |
| Net cash position 2022 | 7.43M 11.34M 620M | Net cash position 2023 | 4.08M 6.24M 341M | EV / Sales 2023 | 2,77,89,011 x |
| P/E ratio 2022 |
-27.4
x | P/E ratio 2023 |
-10.8
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 59.75% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -3.57% | ||
| 1 week | -7.95% | ||
| Current month | -14.74% | ||
| 1 month | -15.62% | ||
| 3 months | -26.36% | ||
| 6 months | -53.71% | ||
| Current year | -40.00% |
1 week
0.08
0.09
1 month
0.080.10
Current year
0.080.19
1 year
0.080.83
3 years
0.082.08
5 years
0.042.08
10 years
0.042.08
| Managers | Title | Age | Since |
|---|---|---|---|
Darren Moulton
COO | Chief Operating Officer | - | - |
Trevor Lockett
BRD | Director/Board Member | - | 01/17/01 |
Guy Carisbrooke
AUD | Comptroller/Controller/Auditor | - | 21/23/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Otto Buttula
CHM | Chairman | - | 28/19/28 |
Louis Panaccio
BRD | Director/Board Member | 67 | 01/17/01 |
Susan MacLeman
BRD | Director/Board Member | - | 31/23/31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/24/29 | 0.081 | -3.57% | 450 920 |
| 24/24/24 | 0.084 | -7.69% | 100,312 |
| 23/24/23 | 0.091 | +3.41% | 80,802 |
| 22/24/22 | 0.088 | -5.38% | 455,962 |
Delayed Quote Australian S.E., April 29, 2024 at 11:40 am IST
More quotes
Rhythm Biosciences Limited is an Australia-based medical diagnostics company. The Company is engaged in the development and commercialization of Australian medical diagnostics technology for sale in domestic and international markets. The Companyâs ColoSTAT a blood-base cancer test, designed for the early detection of colorectal cancer, has been developed initially as an alternative screening test for individuals unable to or unwilling to use available screening modalities. ColoSTAT is indicated to screen adults, aged 40 to 85, at average risk for developing Colorectal Cancer (CRC). The test-kit measures five specific biomarkers in the blood that either increase or decrease in quantity when CRC tumors are present.
Calendar
29/08/2024
- Q4 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -40.00% | 13.47M | |
| -20.15% | 10.82B | |
| +44.65% | 3.25B | |
| -33.94% | 2.11B | |
| -17.21% | 2.08B | |
| -28.03% | 1.48B | |
| +20.31% | 1.02B | |
| -4.37% | 733M | |
| -36.08% | 391M | |
| -45.51% | 383M |
- Stock Market
- Equities
- RHY Stock
